Asset Details
Do you wish to reserve the book?
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Do you wish to request the book?
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
2012
Overview
In a phase 2 trial, patients with hypercholesterolemia received 80 mg atorvastatin and placebo, 10 mg atorvastatin and an antibody to PCSK9, or 80 mg atorvastatin and an antibody to PCSK9 for 8 weeks. Reductions from baseline in LDL cholesterol were 17.3%, 66.2%, and 73.2%, respectively.
Reducing levels of low-density lipoprotein (LDL) cholesterol is a cornerstone of the prevention of cardiovascular disease.
1
,
2
European and U.S. guidelines recommend lowering LDL cholesterol to less than 100 mg per deciliter (2.6 mmol per liter) in persons with established cardiovascular disease and to less than 70 mg per deciliter (1.8 mmol per liter), or by 50% or more, in those at highest risk.
3
,
4
Statins are highly efficacious in lowering LDL cholesterol. However, many patients, especially those with very high initial LDL cholesterol levels and those who have unacceptable side effects with high-dose statins, do not reach recommended target . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Biological and medical sciences
/ Diabetes
/ Disorders of blood lipids. Hyperlipoproteinemia
/ Female
/ Heptanoic Acids - administration & dosage
/ Heptanoic Acids - adverse effects
/ Heptanoic Acids - therapeutic use
/ Humans
/ Hypercholesterolemia - drug therapy
/ Kexin
/ Male
/ Patients
/ Proprotein Convertases - antagonists & inhibitors
/ Pyrroles - administration & dosage
/ Statins
